USPSTF Colon Cancer Screening Recommendations

The U.S. Preventive Services Task Force recommends that all average-risk adults begin colorectal cancer screening at age 45 and continue through age 75, with several approved test options ranging from annual stool tests to colonoscopy every ten years. That starting age dropped from 50 in 2021, driven by rising rates of colorectal cancer in younger adults and modeling data showing that earlier screening offers a favorable tradeoff between lives saved and testing burden. But the recommendation is more layered than a single age cutoff, and the choice of screening method matters more than many people realize.

Why the Starting Age Dropped to 45

Until 2021, the USPSTF recommended screening begin at 50 for people at average risk. The update lowered that threshold to 45, assigning it a grade B recommendation, meaning there is moderate certainty of moderate net benefit. Screening for those 50 to 75 retained its stronger grade A rating.¹ The shift was motivated in large part by the troubling trend of colorectal cancer appearing in younger people. Since the early 1990s, the incidence in younger adults has roughly doubled in the United States.² This pattern is not uniquely American; a global study found early-onset colorectal cancer rates climbing in dozens of countries, with particularly sharp annual increases in New Zealand, Chile, Puerto Rico, and England.³

The USPSTF based its age-45 recommendation on microsimulation modeling that estimated the benefits, burdens, and harms of various screening strategies in a hypothetical group of 40-year-old average-risk Americans. Among the strategies that all three models flagged as efficient, the vast majority specified starting at 45. The estimated life-years gained from screening ranged from roughly 170 to 380 per 1,000 people screened, depending on the test and interval chosen.⁴ The practical implication is straightforward: if you are between 45 and 49 and have not been screened, the USPSTF now considers you overdue.

Which Screening Tests the USPSTF Endorses

The USPSTF does not rank one test above the others. Instead, it lists several approved options and treats any of them as acceptable, reasoning that the best screening test is the one a person will actually complete. The endorsed options fall into three broad categories: stool-based tests, direct visualization procedures, and radiological imaging.

FIT (fecal immunochemical test): Done annually, this at-home test detects hidden blood in stool. It is the most widely used stool test globally and has largely replaced the older guaiac-based version because of better sensitivity. A Cochrane review found that FIT detected colorectal cancer with roughly twice the sensitivity of guaiac tests while maintaining similar specificity.⁵
Multi-target stool DNA (mt-sDNA): Marketed as Cologuard, this combines FIT with DNA biomarkers. It is done every one to three years and catches more precancerous lesions than FIT alone, though at the cost of more false positives.
Colonoscopy: Every 10 years. Considered the reference standard because it can both find and remove polyps in the same session.
Flexible sigmoidoscopy: Every 5 years (or every 10 years combined with annual FIT). Examines only the lower portion of the colon.
CT colonography: Every 5 years. A specialized CT scan that creates a virtual view of the colon without sedation.

An earlier round of USPSTF modeling, from 2016, found that colonoscopy every 10 years, sigmoidoscopy every 10 years paired with annual FIT, CT colonography every 5 years, and annual FIT alone all yielded a roughly comparable balance of screening burden and life-years gained when screening ran from age 50 to 75.⁶ The point is that you are not locked into colonoscopy. If bowel prep and sedation are what keep you from screening, a stool test done faithfully is a legitimate alternative.

How Colonoscopy and Stool Tests Actually Compare

Colonoscopy gets the most attention, but its real-world trial data are more nuanced than its reputation suggests. A landmark European randomized trial (NordICC) followed participants for a median of 10 years and found that being invited for a screening colonoscopy reduced the risk of a colorectal cancer diagnosis by about 18% compared to usual care. The reduction in colorectal cancer death, however, was not statistically significant in the intention-to-screen analysis.⁷ That trial measured the effect of the invitation, not the procedure itself; only about 42% of those invited actually showed up for the colonoscopy. Among people who did get scoped, the cancer reduction was substantially larger. A systematic review and meta-analysis of observational studies estimated that colonoscopy was associated with roughly a 50% reduction in colorectal cancer incidence and about a 60% reduction in colorectal cancer death.⁸

Colonoscopy’s advantage over sigmoidoscopy is its ability to see the entire colon, including the right side where some cancers are harder to detect. A meta-analysis of randomized trials and observational studies found that screening colonoscopy appeared to reduce both distal and proximal colon cancer deaths, while sigmoidoscopy’s benefit was concentrated in the distal colon.⁹

Stool tests work differently. They do not prevent cancer directly; they detect it or its precursors by finding blood or abnormal DNA shed into stool. Their power comes from repetition. A single FIT has moderate sensitivity for cancer and fairly low sensitivity for precancerous polyps, but annual testing over many years catches most cancers eventually. The multi-target stool DNA test has higher one-time sensitivity for both cancer and advanced precancerous lesions. In a head-to-head study, mt-sDNA detected colorectal cancer with about 92% sensitivity compared with about 74% for FIT, and caught advanced precancerous lesions at roughly 42% versus 24%.¹⁰ A separate study in an average-risk screening population confirmed a similar gap: about 46% sensitivity for advanced precancerous lesions with mt-sDNA versus 27% with FIT.¹¹ The tradeoff is specificity: mt-sDNA produces more false positives, meaning more people get sent for colonoscopy who turn out to be fine.

CT Colonography as a Middle Ground

CT colonography, sometimes called virtual colonoscopy, fills a niche for people who want a visual exam of the entire colon without sedation or a scope. You still need bowel prep, but the procedure itself involves a brief CT scan with air inflated into the colon. A large screening trial comparing CT colonography directly to optical colonoscopy found nearly identical detection rates for advanced neoplasia: about 3.2% in the CT group versus 3.4% in the colonoscopy group. The CT group had far fewer polyps removed and zero perforations, compared with seven perforations in the colonoscopy group.¹² The downside is that if something suspicious is found, you still need a follow-up colonoscopy to remove it, which means a second round of prep. And interpretation quality depends on reader experience.¹³

Blood Tests for Colon Cancer Screening

The newest entrant is cell-free DNA blood testing, marketed under the brand name Shield. The FDA approved the first blood-based colorectal cancer screening test in 2024, and the idea of replacing stool collection with a simple blood draw has obvious appeal. The pivotal trial showed that the test caught about 83% of colonoscopy-confirmed colorectal cancers and about 88% of those at stages I through III. Specificity for ruling out advanced neoplasia was about 90%.¹⁴

Those numbers sound decent until you look at what the test misses upstream. Its sensitivity for advanced precancerous lesions was only about 13%. That is a critical gap, because the whole point of screening is to catch polyps before they become cancer. FIT catches advanced precancerous lesions at roughly 22% to 27%, and mt-sDNA catches them at roughly 46%.¹⁵ As of mid-2025, the USPSTF has not yet included blood-based tests in its recommended screening options. The test exists, and some clinicians offer it, but the evidence base for its long-term impact on cancer prevention is still thin. If a blood test is your only alternative to not screening at all, it is better than nothing. If you have access to stool tests or colonoscopy, those remain the stronger choices for catching problems early.

What Happens After a Positive Stool Test

A stool-based screening test that comes back positive is not a diagnosis. It means you need a follow-up colonoscopy to find out what, if anything, is actually there. This is where the screening process breaks down for a troubling number of people. Across U.S. health care organizations between 2017 and 2020, only about 56% of people with a positive stool test completed a follow-up colonoscopy within a year. The largest chunk of those who did get one did so within 90 days, but that still left more than 40% without a timely diagnostic exam.¹⁶

The type of stool test appears to influence follow-up rates. Among adults aged 45 to 49, those who screened with mt-sDNA were far more likely to complete follow-up colonoscopy than those who screened with FIT or older guaiac tests: about 85% versus 35%.¹⁷ That gap likely reflects a mix of factors: the mt-sDNA test comes with a more structured ordering and outreach process, its branded name recognition may make a positive result feel more urgent, and its higher cost may motivate follow-through. In an integrated health system with active patient outreach, the overall rate of timely follow-up colonoscopy was about 60%, and outreach itself boosted completion by roughly 50%.¹⁸ The common barriers are predictable: no gastroenterology appointment scheduled, patient refusal, and no-shows or cancellations.

Risks of Colonoscopy

Colonoscopy is safe for the vast majority of people, but it is not risk-free. The two main serious complications are bleeding and perforation of the colon wall. Population-level data put the rate of significant bleeding at roughly 1 to 2.4 per 1,000 colonoscopies and perforation at about 0.4 to 0.85 per 1,000.¹⁹ Risk goes up substantially when polyps are removed during the procedure: the odds of bleeding or perforation after polypectomy are roughly six times higher than after a colonoscopy with no polyp removal.²⁰ Older age and more medical conditions also raise the risk. For context, perforation rates in large studies range from about 0.5 to 8.5 per 10,000 colonoscopies, depending on the population and whether the procedure was diagnostic or therapeutic.²¹ These are small numbers, but they are not zero, and they matter when weighing the benefits of screening for people at the upper end of the age range or with significant health problems.

When to Stop Screening

The USPSTF gives screening for ages 76 to 85 a grade C, meaning it offers small net benefit and the decision should be individualized. Adults in this range who have never been screened stand to benefit more than those with a long history of normal results.²² The U.S. Multi-Society Task Force on Colorectal Cancer takes a similar stance and adds a hard stop: screening is not recommended after age 85, because the risks of complications and competing causes of death outweigh the potential gain from finding and removing polyps.²³

Modeling work has tried to personalize stop ages more precisely by factoring in comorbidities and screening history. For a 76-year-old woman with a perfect screening record, more than 150 women would need to be screened to gain one life-year per 1,000 people. But an unscreened woman with no comorbidities could benefit from a first screening colonoscopy as late as age 90. At the other extreme, individuals with severe comorbidities who have been regularly screened should consider stopping by age 66 or even younger.²⁴ A separate modeling study estimated that the optimal screening stop ages for people with no, mild, moderate, and severe comorbidities were approximately 76, 74, 72, and 66, respectively.²⁵ The takeaway: screening duration is not one-size-fits-all. Life expectancy and overall health condition matter more than calendar age alone.

Screening Disparities in the United States

Overall, roughly two-thirds of eligible U.S. adults are up to date with colorectal cancer screening, but that average masks significant gaps. Black Americans have the highest colorectal cancer incidence and mortality of any racial or ethnic group in the country, driven by a combination of socioeconomic barriers, insurance gaps, dietary factors, and possibly biological differences in tumor biology.²⁶ In a large cohort of disadvantaged patients receiving care at federally supported community health centers in the Southeast, screening rates were significantly lower among Black patients (34%) than White patients (40%).²⁷

Hispanic adults with limited English proficiency face some of the widest gaps. Across all levels of chronic disease burden, Hispanic respondents with limited English proficiency were less likely than non-Hispanic White adults to be up to date with screening.²⁸ These disparities are not just about personal choice; they trace back to insurance coverage, access to gastroenterologists, clinic infrastructure, and language barriers that compound at every step of the screening process.

What Actually Gets More People Screened

Mailed outreach programs, where health systems send stool test kits directly to patients’ homes, consistently boost screening rates compared to usual care. A cluster randomized trial in community health clinics found that mailing FIT kits raised the proportion of people screened from about 14.5% to about 18.3%.²⁹ A more recent trial compared mailed FIT-DNA kits to mailed FIT kits in community health centers and found screening participation about five percentage points higher in the FIT-DNA group at 180 days (roughly 32% versus 27%).³⁰

Cost-sharing also plays a role. When the Affordable Care Act eliminated copays for preventive colonoscopy, the rural-urban gap in colonoscopy rates shrank by about 40%.³¹ A remaining problem was that follow-up colonoscopies after a positive stool test were often reclassified as diagnostic rather than preventive, sticking patients with unexpected bills. When policy changes eliminated cost-sharing for those follow-up procedures as well, there was an immediate jump of about 41% in the rate of follow-up colonoscopy completion.³² Financial barriers, in other words, are not just theoretical; removing them measurably changes behavior.

How Other Countries Handle Screening

The USPSTF’s approach is notably broad compared with most international guidelines. A systematic review of global screening recommendations found that many European countries and Canada rely on a narrower set of test options, typically favoring stool-based tests over colonoscopy as the primary screening tool. Canada’s task force recommends FIT or guaiac testing every two years or sigmoidoscopy every 10 years for adults 60 to 74, with a weaker recommendation for the 50-to-59 group and a specific note that colonoscopy is not recommended as a primary screening test. The European guidelines similarly favor FIT every one to two years, citing strong evidence for stool-based programs and more limited evidence for colonoscopy. Germany is an outlier in Europe, preferring colonoscopy every 10 years as the first-line option.³³

These differences are partly philosophical and partly practical. Colonoscopy requires trained endoscopists, sedation infrastructure, and recovery time, all of which limit how many people a health system can screen. Stool-based programs can be deployed at population scale with far less infrastructure. The USPSTF sidesteps this debate by endorsing all validated options equally and leaving the choice to patients and clinicians, which works in a system where colonoscopy capacity exists but access remains uneven.

Emerging Biomarkers on the Horizon

Researchers are exploring ways to make stool tests smarter by adding microbial biomarkers. One line of work focuses on Fusobacterium nucleatum, a gut bacterium found at elevated levels in colorectal tumors. When researchers measured this bacterium in leftover material from standard FIT samples and combined it with the FIT result, the sensitivity for detecting colorectal cancer jumped from about 73% to about 92%, and the sensitivity for advanced adenomas climbed from about 16% to about 39%.³⁴ A separate study confirmed the feasibility of detecting this bacterium in FIT sample leftovers using highly sensitive molecular techniques, with perfect sensitivity for cancer detection in FIT-positive samples, though specificity was only about 50%.³⁵ None of this is ready for clinical practice yet, but it points toward a future where stool tests could approach colonoscopy-level sensitivity for precancerous lesions without requiring bowel prep, sedation, or a day off work.